What Sextant Sees

GSS: 53 | Resonance: 35 | Tension: condensing
Active Patterns: FOMO Ignition, Wrong Consensus Meets Deadline, The Compression Signal
Theoretical: None
Dimensions: M:6.2 C:6.0 D:3 S:3 CP:1 Mg-Q:6 Mg-T:7
Velocity: gaining: C_volume_anomaly +9, C_options_anomaly +7 (2 scans)

What Sextant Sees

GSS: 53 | Resonance: 35 | Tension: condensing
Active Patterns: fomo_ignition, wrong_consensus, compression_signal
Theoretical: None
Dimensions: M:6 C:8 D:10 S:6 CP:1 Mg-Q:6 Mg-T:7
Velocity: gaining: C_volume_anomaly +9, C_options_anomaly +7 (2 scans)

Wave Life Sciences makes RNA medicines that edit genes.

Wave controls WVE-007, an obesity drug that works by turning down a gene linked to fat accumulation and requires dosing only once or twice yearly. The company has $602 million cash with runway into Q3 2028 and operates in the RNA editing space where few competitors exist. Wave also has an expanded GSK collaboration worth up to $2.8 billion in potential milestones.

Wave's stock plunged 56% on March 26 after Phase 1 obesity data showed their drug worked at lower doses but failed to scale at higher doses. The 240mg dose produced 14% visceral fat reduction at six months, but the 400mg dose showed minimal efficacy. This "lack of more is better" efficacy signaled a potential ceiling for the drug's potency in a market dominated by GLP-1 drugs that deliver double-digit weight loss. The collapse comes as small-cap biotech speculation ends and investors rotate into the "Great Rotation" toward old economy sectors.

Watch for Phase 2a multidose results in Q2 2026 when Wave tests higher-BMI patients (35-50 kg/m²) with comorbidities. FDA regulatory feedback on the accelerated approval pathway for their other drug WVE-006 is expected mid-2026.

Upside: Oppenheimer maintains $32 price target, calling the 400mg data a statistical outlier that Phase 2a will fix. Downside: Stock fell below 200-day moving average for first time since December 2025.

Full entry window, exit conditions, and score trajectory available to Pro members at damonskyeresearch.com

The author may hold positions in securities discussed in this publication. All positions, if any, will be consistent with the analytical thesis presented. DamonSkye Research discloses material holdings at the time of publication. This is not investment advice. See full disclaimer.